Evidence map›Paper›PMID 42619025›Full record

ArticleChemMedChem2026

Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study.

Jonathan Trapala, Laura I Álvarez-Añorve, Nathaly Vasquez-Martínez, Erika Chavira-Suárez, Luz Vásquez-Bochm, Deyamira Matuz-Mares, Francisco Cortés-Benítez, Martin González-Andrade

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan TrapalaDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
Laura I Álvarez-AñorveDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID https://orcid.org/0000-0002-4321-3642
Nathaly Vasquez-MartínezDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID https://orcid.org/0000-0003-2154-1802
Erika Chavira-SuárezDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID https://orcid.org/0000-0002-1012-2760
Luz Vásquez-BochmDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID https://orcid.org/0009-0001-8052-7800
Deyamira Matuz-MaresDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
Francisco Cortés-BenítezLaboratorio de Síntesis y Aislamiento de Sustancias Bioactivas, Departamento de Sistemas Biológicos, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana - Unidad Xochimilco, Ciudad de México, México.ORCID https://orcid.org/0000-0002-3954-8220
Martin González-AndradeDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID https://orcid.org/0000-0002-8910-3035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although chlorogenic acid, suramin, ursolic acid, and the glycyrrhetinic acid derivative FC122 are individually known PTP1B inhibitors, no study has systematically characterized how mechanistic diversity determines the pharmacological outcome of their combinations. Here, we integrate experimental enzyme kinetics, molecular docking, molecular dynamics (MD), and membrane permeability simulations to address this question. Individual inhibitory potencies ranked SUR > FC122 > UA > CGA (IC

Indexed as

Enzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 1HumansKineticsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipEnzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanenzyme kineticsmolecular dockingmolecular dynamicsPTP1B inhibitiontype 2 diabetes mellitus

Identifiers

PMID42619025
PMCPMC13490622

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.